{"DataElement":{"publicId":"7449895","version":"1","preferredName":"Total Tumor Tissue Segment Comment Text","preferredDefinition":"A free text field to provide additional information regarding the entire malignant neoplasm tissue specimen collection process.","longName":"7449876v1.0:6847557v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7449876","version":"1","preferredName":"Total Tumor Tissue Segment Comment","preferredDefinition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._A tumor sample, or entire tumor that is removed for microscopic examination._Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis._A written explanation, observation or criticism added to textual material.","longName":"7449874v1.0:2223274v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"7449874","version":"1","preferredName":"Total Tumor Tissue Tumor Segment","preferredDefinition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition.:A tumor sample, or entire tumor that is removed for microscopic examination.:Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis.","longName":"C25304:C18009:C162622","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total","conceptCode":"C25304","definition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Tumor Tissue Sample","conceptCode":"C18009","definition":"Tissue sample that contains an abnormal cellular infiltrate forming a solid mass. The abnormal cellular component can be benign or malignant. Tumor samples are obtained for microscopic examination and/or molecular analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Segment","conceptCode":"C162622","definition":"Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0A025AE-3633-368B-E053-4EBD850AF98F","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-01","modifiedBy":"ONEDATA","dateModified":"2020-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223274","version":"1","preferredName":"Comment","preferredDefinition":"A written explanation or criticism or illustration that is added to a book or other textual material.","longName":"C25393","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Comment","conceptCode":"C25393","definition":"A written explanation, observation or criticism added to textual material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629FF0E-4B75-2183-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0A10891-9859-4A89-E053-4EBD850A07C1","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-01","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeDescription":"1/26/21 jk Released per SME (NGM) review and approval. 10/1/20 jk created for Solid Tumor Procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6847557","version":"1","preferredName":"4000 Character Text","preferredDefinition":"The words of something written.","longName":"6847557v1.0","context":"OCCPR","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"4000","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F78F00C-3668-5BB9-E053-F662850A122E","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-06","modifiedBy":"KNABLEJ","dateModified":"2020-02-12","changeDescription":"1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  8/6/19 jk created for multiple CPTAC CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"7409064","version":"1","longName":"All Procurement CRFs","context":"OCCPR"},{"publicId":"7409065","version":"1","longName":"Solid Tumor Specimen","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Comments","type":"Preferred Question Text","description":"Comments","url":null,"context":"OCCPR"},{"name":"CPTAC-Tumor-Procurement-1","type":"Coding Instructions","description":"Enter actual ischemic time if applicable","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0A05086-0C45-3690-E053-4EBD850AD245","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-01","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeDescription":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/1/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}